Patent directory · USPTO A61K / A61P
Patents matching “Mirati Therapeutics, Inc.”
34 pharma patents match "Mirati Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 34 pharmaceutical patents matching "Mirati Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted -
US 12336995
Combination therapies
granted -
US 12286431
Crystalline forms of a KRas G12C inhibitor
granted -
US 12281113
Crystalline forms of a KRas G12C inhibitor
granted -
US 12280055
Combination therapies
granted -
US 12252493
Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
granted -
US 12208099
Combination therapies
granted -
US 12171765
Combination therapies using PRMT5 inhibitors for the treatment of cancer
granted -
US 12128048
Combination therapies using PRMT5 inhibitors for the treatment of cancer
granted -
US 11999753
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 11964989
KRas G12D inhibitors
granted -
US 11932633
KRas G12C inhibitors
granted -
US 11890285
Combination therapies
granted -
US 11548888
KRas G12C inhibitors
granted -
US 11492351
MTA-cooperative PRMT5 inhibitors
granted -
US 11485738
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted -
US 11479551
MTA-cooperative PRMT5 inhibitors
granted -
US 11453683
KRas G12D inhibitors
granted -
US 11267812
KRAS G12C inhibitors
granted